Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
|Slideshows|August 16, 2018
At the Heart of Depression: 3 New Studies
Author(s)Mark L. Fuerst
New research brings us closer to learning about the associations between psychological states, quality of life, and cardiovascular health.
Advertisement
Advertisement
Related to this article
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
4
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
5